Clinical and Guideline Updates on Systemic Therapies for Hepatocellular Carcinoma

Join us for this dynamic 1-hour CPE-certified live webinar, in which an expert pharmacist panel will discuss current guidance and emerging strategies for treating patients with early and advanced HCC. Sign up now! 

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.


Welcome and Introduction

Current Frontline Treatment of Advanced HCC

Emerging Therapies for Advanced HCC

Optimal Sequencing of Second-line Therapy and Beyond

Investigational Approaches to Resection and Locoregional Treatment

Audience Questions


Date / Time
Event Details


Courtney C. Cavalieri, PharmD, BCOP

Clinical Oncology Pharmacist
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah

Amber Draper, PharmD, BCOP

Oncology Clinical Pharmacy Specialist
Clinical Coordinator, 
Emory Healthcare Winship Cancer Institute
Atlanta, Georgia

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and competence of pharmacists in the management of patients with HCC.

Target Audience
The target audience for this activity is pharmacists, including clinical, managed care, and specialty pharmacists, who care for patients with HCC as well as other stakeholders in hematology/oncology practice.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate clinical data on the use of systemic treatment approaches for patients with early or intermediate-stage HCC
  • Design optimal, individualized care plans for patients with advanced HCC, both in the frontline and second-line treatment settings
  • Develop strategies to identify and mitigate unique adverse events associated with novel targeted therapies in patients with HCC
  • Identify patients who may benefit from ongoing clinical trials based on tumor characteristics, previous treatment, and patient characteristics and preferences


CE Accreditation


ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-22-159-L01-P has been assigned to this live application-based activity (initial release date 5/5/2022). This activity is approved for 1.0 contact hours (0.1 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at, and proof of completion will be posted in NABP CPE Monitor profiles.

ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. Faculty disclosures will be provided prior to the start of the CE activity.